Current role of neoadjuvant and adjuvant systemic therapy for high-risk localized prostate cancer. [electronic resource]
Producer: 20140110Description: 366-71 p. digitalISSN:- 1473-6586
- Androgen Antagonists -- adverse effects
- Antineoplastic Agents, Hormonal -- adverse effects
- Chemoradiotherapy -- adverse effects
- Humans
- Kallikreins -- blood
- Male
- Neoadjuvant Therapy
- Neoplasms, Hormone-Dependent -- blood
- Prostate-Specific Antigen -- blood
- Prostatectomy -- adverse effects
- Prostatic Neoplasms -- blood
- Risk Factors
- Time Factors
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Review
There are no comments on this title.
Log in to your account to post a comment.